{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:46:15Z","timestamp":1776091575146,"version":"3.50.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Medulloblastoma is the most common and lethal pediatric malignant brain tumor. It comprises four main molecular subgroups: WNT-activated, SHH-activated, Group 3, and Group 4. Medulloblastoma treatment is surgical resection, craniospinal radiation, and chemotherapy. However, many patients do not respond to therapy, and most suffer severe side effects. Cancer immunotherapy targeting immune checkpoints (IC) (PD-1, PD-L1, and CTLA4) has been getting disappointing outcomes in brain tumors. Nevertheless, other less explored immune checkpoints may be promising candidates for medulloblastoma therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>In the present study, we aimed to characterize the expression profile of 19 immune checkpoints in medulloblastoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed 88 formalin-fixed paraffin-embedded medulloblastomas previously classified for each molecular subgroup and three non-tumoral brain tissue. mRNA levels of 19 immune checkpoint-related genes were quantified using the nCounter (PanCancer Immune Profiling Panel) assay. Further <jats:italic>in silico<\/jats:italic> analysis was performed in two larger public microarray datasets, one of which enabled comparisons between tumoral and non-tumoral tissues. Immunohistochemistry of PD-L1 was performed in a subset of cases. Microsatellite instability was also molecularly analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We observed an absence of expression of the canonic ICs, namely <jats:italic>PDCD1<\/jats:italic> (PD-1), <jats:italic>CD274<\/jats:italic> (PD-L1), and <jats:italic>CTLA4<\/jats:italic>, as well as <jats:italic>CD80, CD86, BTLA, IDO1, CD48, TNFSF14, CD160, CEACAM1<\/jats:italic>, and <jats:italic>CD244.<\/jats:italic> PD-L1 protein expression was also practically absent. We found higher mRNA levels of <jats:italic>CD24, CD47<\/jats:italic>, <jats:italic>CD276<\/jats:italic> (B7-H3), and <jats:italic>PVR<\/jats:italic>, and lower mRNA levels of <jats:italic>HAVCR2<\/jats:italic>, <jats:italic>LAG3<\/jats:italic>, and <jats:italic>TIGIT<\/jats:italic> genes, with significant differences across the four molecular subgroups. Compared to the non-tumor tissues, the expression levels of <jats:italic>CD276<\/jats:italic> in all subgroups and <jats:italic>CD24<\/jats:italic> in SHH, Group 3, and Group 4 subgroups are significantly higher. The <jats:italic>in silico<\/jats:italic> analysis confirmed the expression profile found in the Brazilian cohort, including the lower\/absent expression of the canonic ICs. Moreover, it confirmed the overexpression of <jats:italic>CD24<\/jats:italic> and <jats:italic>CD276<\/jats:italic> in medulloblastomas compared with the non-tumor tissue. Additionally, <jats:italic>CD276<\/jats:italic> and CD24 high levels were associated with worse survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results highlight the low or absence of mRNA levels of the canonic targetable ICs in medulloblastomas. Importantly, the analysis revealed overexpression of <jats:italic>CD24<\/jats:italic> and <jats:italic>CD276<\/jats:italic>, which can constitute prognostic biomarkers and attractive immunotherapy targets for medulloblastomas.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1062856","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T08:36:16Z","timestamp":1675758976000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets"],"prefix":"10.3389","volume":"14","author":[{"given":"Rui Ferreira","family":"Marques","sequence":"first","affiliation":[]},{"given":"Daniel Antunes","family":"Moreno","sequence":"additional","affiliation":[]},{"given":"Luciane","family":"da Silva","sequence":"additional","affiliation":[]},{"given":"Leticia Ferro","family":"Leal","sequence":"additional","affiliation":[]},{"given":"Fl\u00e1via Escremim","family":"de Paula","sequence":"additional","affiliation":[]},{"given":"Iara","family":"Santana","sequence":"additional","affiliation":[]},{"given":"Gustavo","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Fabiano","family":"Saggioro","sequence":"additional","affiliation":[]},{"given":"Luciano","family":"Neder","sequence":"additional","affiliation":[]},{"given":"Carlos Almeida","family":"Junior","sequence":"additional","affiliation":[]},{"given":"Bruna","family":"Man\u00e7ano","sequence":"additional","affiliation":[]},{"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0063-6","article-title":"Medulloblastoma","volume":"5","author":"Northcott","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2016.59939","article-title":"Medulloblastoma: Molecular pathways and histopathological classification","volume":"12","author":"Borowska","year":"2016","journal-title":"Arch Med Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-0958-8","article-title":"Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas","volume":"123","author":"Kool","year":"2012","journal-title":"Acta Neuropathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12508","article-title":"Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma","volume":"38","author":"Leal","year":"2018","journal-title":"Neuropathology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cnr2.1146","article-title":"Medulloblastoma: Challenges and advances in treatment and research","volume":"2","author":"Martirosian","year":"2019","journal-title":"Cancer Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/ITT.S198162","article-title":"Immunotherapy for medulloblastoma: Current perspectives","volume":"9","author":"Villano","year":"2020","journal-title":"ImmunoTargets Theraoy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13215387","article-title":"Immunotherapy in Medulloblastoma : Current state of research, challenges, and future perspectives","volume":"16","author":"Voskamp","year":"2021","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2190-1","article-title":"Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors","volume":"129","author":"Blumenthal","year":"2016","journal-title":"J Neuro-Oncology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001339","article-title":"Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: A single institutional experience","volume":"41","author":"Gorsi","year":"2019","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09854-1","article-title":"Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches","volume":"39","author":"Menyh\u00e1rt","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer Mol Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00874-9","article-title":"Immunosuppression in medulloblastoma: Insights into cancer immunity and immunotherapy","volume":"22","author":"Audi","year":"2021","journal-title":"Curr Treat Options Oncol Curr Treat Options Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2020.04.207","article-title":"Expression of GNAS, TP53, and PTEN improves the patient prognostication in sonic hedgehog (SHH) medulloblastoma subgroup","volume":"22","author":"da Silva","year":"2020","journal-title":"J Mol Diagn"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11060-022-03965-1","article-title":"Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: A multicentric study","volume":"157","author":"Moreno","year":"2022","journal-title":"J Neuro-Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03675-6","article-title":"Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide","volume":"151","author":"Gomes","year":"2021","journal-title":"J Neuro-Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-022-01104-y","article-title":"Association of microsatellite instability (MSI) status with the 5-year outcome and genetic ancestry in a large Brazilian cohort of colorectal cancer","volume":"30","author":"Berardinelli","year":"2022","journal-title":"Eur J Hum Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2013.256","article-title":"Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: Correlation with ancestry markers","volume":"22","author":"Campanella","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25611","article-title":"Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients","volume":"9","author":"Berardinelli","year":"2018","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221127678","article-title":"Cancer immune profiling unveils biomarkers, immunological pathways, and cell type score associated with glioblastoma patients\u2019 survival","volume":"14","author":"Moreno","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02809","article-title":"The emerging role of CD244 signaling in immune cells of the tumor microenvironment","volume":"9","author":"Agresta","year":"2018","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/jnen\/nly045","article-title":"Poliovirus receptor (CD155) expression in pediatric brain tumors mediates oncolysis of medulloblastoma and pleomorphic xanthoastrocytoma","volume":"77","author":"Thompson","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11030356","article-title":"Size matters: The functional role of the CEACAM1 isoform signature and its impact for NK cell-mediated killing in melanoma","volume":"11","author":"Helfrich","year":"2019","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2020","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41416-021-01453-3","article-title":"Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers","volume":"126","author":"Zhou","year":"2022","journal-title":"Br J Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/1471-2164-13-296","article-title":"ReadqPCR and NormqPCR: R packages for the reading, quality checking and normalisation of RT-qPCR quantification cycle (Cq) data","volume":"13","author":"Perkins","year":"2012","journal-title":"BMC Genomics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral heterogeneity within medulloblastoma subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 expression in lung cancer","volume":"11","author":"Yu","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/JCLINPATH-2020-206832","article-title":"PD-L1 expression by tumor proportion score (TPS) and combined positive score (CPS) are similar in non-small cell lung cancer (NSCLC)","volume":"74","author":"De Marchi","year":"2021","journal-title":"J Clin pathol J Clin Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7100137","article-title":"Immunotherapy for pediatric brain tumors","volume":"7","author":"Sayour","year":"2017","journal-title":"Brain Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2019.04.025","article-title":"PD-1\/PD-L1 blockade in paediatric cancers: What does the future hold","volume":"457","author":"Moreno-Vicente","year":"2019","journal-title":"Cancer Lett"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-115","article-title":"Analysis of microsatellite instability in medulloblastoma","volume":"11","author":"Viana-Pereira","year":"2009","journal-title":"Neuro-Oncology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2021.1998266","article-title":"Microsatellite instability-high is rare events in refractory pediatric solid tumors","volume":"39","author":"Yoshida","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24951","article-title":"PD-L1 expression in medulloblastoma: An evaluation by subgroup","volume":"9","author":"Martin","year":"2018","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2886-5","article-title":"PD-1\/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population","volume":"139","author":"Hwang","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/2162402X.2017.1398877","article-title":"Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma","volume":"7","author":"Vermeulen","year":"2018","journal-title":"OncoImmunology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.21.00286","article-title":"Immune checkpoint inhibition as single therapy for synchronous cancers exhibiting hypermutation: An IRRDC study","author":"Henderson","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/85339","article-title":"B7-H3: A costimulatory molecule for T cell activation and IFN-\u03b3 production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737546","article-title":"Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity","volume":"37","author":"Castriconi","year":"2007","journal-title":"Eur J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2559.2008.03070.x","article-title":"Small round blue cell tumours: Diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule","volume":"53","author":"Gregorio","year":"2008","journal-title":"Histopathology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0210665","article-title":"Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells","volume":"14","author":"Robson","year":"2019","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33249","article-title":"Novel insights into the function of CD24: A driving force in cancer","volume":"148","author":"Altevogt","year":"2021","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm12081235","article-title":"CD24: A novel target for cancer immunotherapy","volume":"12","author":"Panagiotou","year":"2022","journal-title":"J Pers Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/2162402X.2018.1462430","article-title":"Subgroup-specific immune and stromal microenvironment in medulloblastoma","volume":"7","author":"Bockmayr","year":"2018","journal-title":"OncoImmunology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103014","article-title":"CD47: the next checkpoint target for cancer immunotherapy","volume":"152","author":"Feng","year":"2020","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRP\u03b1 anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Sci Trans Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41423-018-0168-y","article-title":"Targeting PVR (CD155) and its receptors in anti-tumor therapy\u2019","volume":"16","author":"Ku\u010dan Brli\u0107","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.41105","article-title":"B7-H3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-022-01610-7","article-title":"Overcoming the blood\u2013brain barrier for the therapy of malignant brain tumor: Current status and prospects of drug delivery approaches","volume":"20","author":"Mitusova","year":"2022","journal-title":"J Nanobiotechnol BioMed Cent"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1062856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T08:36:19Z","timestamp":1675758979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1062856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2023.1062856"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1062856","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"article-number":"1062856"}}